Mironid raised $46M in a Series B round announced on August 7, 2026. Targeted therapeutic innovation to improve health and quality of life.
Targeted therapeutic innovation to improve health and quality of life.
Mironid, based in Newhouse, United Kingdom, announced $46M in Series B financing on August 7, 2026.
Participants include BioGeneration Ventures, Epidarex Capital, Roche Venture Fund, Scottish National Investment Bank, Sofinnova Partners, University of Strathclyde.
The latest generation of AI models achieve breakthrough performance by using vastly more tokens to solve complex problems. As frontier models become more sophisticated, demand is compounding faster than today’s infrastructure can scale.
World’s first community-driven, open-source artificial intelligence (AI) company.